Hematopoietic stem cell transplantation (HSCT) remains a vital treatment for a variety of haematologic malignancies and non‐malignant disorders. The procedure, involving the transfer of multipotent ...

The Global Peripheral T-Cell Lymphoma Market is poised for significant growth, driven by a rising incidence of lymphoma and adoption of novel targeted therapies and immunotherapies. Peripheral T-cell ...

Exploratory analyses of immune reconstitution biomarkers from a Ph1b study of an investigational, oral, live biotherapeutic, SER-155, in adult allo-HCT. The impact of the use of hypomethylating agents ...

A new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, according to a study ...

Stem cell transplants remain essential for blood cancers, with expanded donor options including half-matched family members and umbilical cord blood. Cyclophosphamide has improved graft-versus-host ...

At Liv Hospital, specialists emphasize that stem cell therapy isn’t a one-size-fits-all solution. Instead, it is carefully indicated for specific diseases, patient profiles, and treatment ...

Blood cancer patients who may have previously struggled to find a donor for transplantation now have more options. A new study shows that patients achieve good outcomes with a partial match drawn from ...

Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a poster at the upcoming 2026 Tandem ...